Bastion Asset Management Inc. Acquires 135,294 Shares of Certara, Inc. $CERT

Bastion Asset Management Inc. raised its holdings in Certara, Inc. (NASDAQ:CERT) by 242.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 191,105 shares of the company’s stock after buying an additional 135,294 shares during the quarter. Bastion Asset Management Inc. owned 0.12% of Certara worth $1,137,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Wasatch Advisors LP grew its holdings in Certara by 45.7% in the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock worth $158,335,000 after purchasing an additional 4,244,230 shares during the period. Jefferies Financial Group Inc. bought a new position in shares of Certara during the 4th quarter worth about $26,706,000. Deerfield Management Company L.P. boosted its position in shares of Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after purchasing an additional 2,813,438 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Certara by 133.4% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock valued at $20,024,000 after buying an additional 1,299,109 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Certara by 27.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after buying an additional 1,165,064 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analysts Set New Price Targets

CERT has been the topic of several recent research reports. BMO Capital Markets cut their price target on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. KeyCorp dropped their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Barclays reduced their price objective on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Craig Hallum lowered their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Certara currently has a consensus rating of “Hold” and a consensus price target of $8.85.

Certara Stock Up 3.1%

CERT opened at $7.28 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The company’s 50-day moving average is $5.76 and its 200 day moving average is $6.71. Certara, Inc. has a fifty-two week low of $4.45 and a fifty-two week high of $13.88. The firm has a market capitalization of $1.13 billion, a P/E ratio of -72.80 and a beta of 1.46.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business’s revenue was up .8% compared to the same quarter last year. During the same quarter last year, the business posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Research analysts expect that Certara, Inc. will post 0.24 earnings per share for the current fiscal year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.